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Atherosclerotic vascular disease is a chronic inflamma-tion of the arterial vessel wall causing a severe socio-
economic burden in western socities.1 A commonly used 
interventional technique to widen arteries narrowed by ath-
erosclerotic lesions is angioplasty. In turn, this intervention 
induces severe arterial damage, possibly leading to the recur-
rence of stenosis, termed restenosis. Although the incidence 
of restenosis has declined because of the use of drug-eluting 
stents and antiplatelet therapy, further optimization of angio-
plasty remains an important topic.2
Restenosis after angioplasty is the consequence of an 
inflammatory response to arterial damage exaggerating the 
growth of the neointima. Important determinants of neointima 
formation are endothelial denudation, leukocyte recruitment, 
and neointimal hyperplasia, resulting in the thickening of the 
arterial wall and decreased arterial lumen.3
Annexin A1 (AnxA1), a formyl peptide receptor 2 ligand, 
promotes resolution of inflammation engaging various impor-
tant pathways.4 As an example, AnxA1 has been shown to 
negatively regulate leukocyte trafficking,5,6 to improve dead 
cell clearance by macrophages,7 and to induce polarization 
of macrophages toward an anti-inflammatory phenotype.8 All 
these qualities harbor the potential for AnxA1 to influence 
vascular repair, and we, therefore, studied the phenotype of a 
mouse lacking AnxA1 in a model of mechanical wire injury.
Materials and Methods
Material and Methods are available in the online-only Data 
Supplement.
Results
To identify the source of AnxA1, we stained healthy and 
injured carotid arteries from Apoe−/− mice fed a high-fat diet, 
for AnxA1 (Figure I in the online-only Data Supplement), 
along with specific markers for endothelial cells (CD31), 
smooth muscle cells (α-smooth muscle actin), and macro-
phages (Mac2). In either case, AnxA1 was found to primarily 
colocalize with endothelial cells and macrophages (Figure 1A 
and 1B; Figure II in the online-only Data Supplement). 
Similar observations were made in human iliac artery sections 
obtained after percutaneous transluminal angioplasty (Figures 
II and III in the online-only Data Supplement). Likewise, 
AnxA1 expression was prominent in cell cultures of mouse 
and human endothelial cells and macrophages, whereas little 
staining was found in smooth muscle cells (Figure IV in the 
online-only Data Supplement). On cell activation, AnxA1 can 
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be externalized to the cell membrane or secreted into the extra-
cellular fluids9 and can, therefore, be detected in the plasma by 
ELISA. Interestingly, data from bone marrow transplant stud-
ies (Figure VA in the online-only Data Supplement) indicate 
that plasma AnxA1 may derive from circulating and vessel-
resident cells. In fact, no differences in plasma AnxA1 were 
found between Apoe−/− mice reconstituted with Apoe−/−AnxA1−/− 
bone marrow and Apoe−/−AnxA1−/− mice reconstituted with 
Apoe−/− bone marrow. Of note, AnxA1 plasma levels from 
both groups were lower when compared with Apoe−/− mice 
receiving a high-fat diet for 4 weeks (Figure VA and VB in the 
online-only Data Supplement), thus, suggesting a contribution 
of either source to circulating plasma levels. Remarkably, an 
additional increase of AnxA1 protein level was observed in 
mice that were both fed a high-fat diet and subjected to wire 
injury (Figure VB in the online-only Data Supplement).
To study a potential role of AnxA1 during arterial injury, we 
correlated neointima sizes in Apoe−/− mice 4 weeks after wire 
Figure 1. Annexin A1 (AnxA1) negatively 
correlates with neointima area after arte-
rial injury. Sections of carotid arteries, 
obtained from Apoe−/− mice fed a high-fat 
diet for 4 weeks, were stained for AnxA1. 
Stainings were made in undamaged (A) or 
damaged vessels (B) in conjunction with 
antibodies to endothelial cells (CD31), 
smooth muscle cells (αSMC), or macro-
phages (Mac2). Scale bars represent 25 
μm. C, AnxA1 plasma levels, obtained 
from Apoe−/− mice 4 weeks after arterial 
damage, were correlated with carotid 
neointima area (Pearson correlation, 
n=14). D, Correlation of neointimal AnxA1 
area with carotid neointima size (Pearson 
correlation, n=14).
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injury with AnxA1 plasma levels measured by ELISA (Figure 1C) 
or the degree of lesional AnxA1 expression (Figure 1D). In both 
analyses, a negative correlation was perceived suggestive of a 
protective effect of AnxA1 in healing after injury.
To establish a causal contribution of AnxA1 in arterial 
healing, Apoe−/− and Apoe−/−Anxa1−/− mice were subjected to 
wire injury while fed a high-cholesterol diet. No significant 
differences were observed in myeloid cell counts in the blood, 
bone marrow, and spleen (Table I in the online-only Data 
Supplement). In sections obtained 4 weeks after the instiga-
tion of injury, Apoe−/−Anxa1−/− mice showed a marked increase 
in neointima size, corroborating a protective effect of AnxA1 
(Figure 2A). To reveal the cell type that is responsible for the 
aggravation of neointima growth, the cellular composition of 
the neointima was characterized. No changes were observed 
in the number of smooth muscle cells present in the neointima 
(Figure 2B). However, in line with the predominant expression 
of AnxA1 in macrophages, we evidenced an expansion of these 
cells in neointimal lesions obtained from AnxA1-deficient 
mice (Figure 2C and 2D; Figure VI in the online-only Data 
Supplement), which can possibly be attributed to a larger frac-
tion of proliferating macrophages in these mice (Figure 2E). In 
addition, more M-CSF (macrophage colony-stimulating factor) 
staining was found in neointima sections from Apoe−/−Anxa1−/−, 
which could explain an increase in macrophage proliferation 
(Figure 2F). Interestingly, an inhibitory effect of AnxA1 on the 
expression (Figure VIIA in the online-only Data Supplement) 
and release (Figure VIIB in the online-only Data Supplement) 
of M-CSF from macrophages was observed in vitro. Of note, 
the endothelial lining was equally restored in AnxA1-deficient 
mice (Figure VIII in the online-only Data Supplement).
Discussion
In the present study, we examined the role of AnxA1 in heal-
ing after arterial injury. We witnessed a prominent expression 
of AnxA1 in endothelial cells and macrophages residing in 
the neointima. Lesional AnxA1 and plasma AnxA1 levels 
negatively correlated with neointima area, suggestive of a 
reparative role of AnxA1. In AnxA1-null mice, neointima 
development was mainly aggravated by the accumulation of 
proliferating macrophages in the injured tissue.
Inflammatory macrophages are histologically identi-
fied within neoatherosclerosis in human coronary implants 
and stents.10 Arterial macrophage accumulation is controlled 
by different mechanisms, including apoptosis, recruitment, 
and proliferation.11 In previous work, it has been shown that 
AnxA1 and its N-terminal fragment Ac2-26 counteract chemo-
kine-induced integrin activation by inhibition of Rap1 activa-
tion in monocytes and, therefore, restrains adhesion to large 
arteries.5 Consequently, enhanced recruitment of monocytes 
Figure 2.  Neointima expansion is aggravated in annexin A1 (AnxA1)–deficient mice. Apoe−/− and Apoe−/−Anxa1−/− mice were subjected 
to wire injury and fed an atherogenic high-fat diet 1 week prior and 4 weeks after injury. A, Quantification of the carotid neointima area 
in elastic tissue fibers—Verhoeff’s van Gieson (EVG)-stained section. B, Quantification of α-smooth muscle actin (αSMA+) cells in abso-
lute numbers. C, Quantification of total Mac2+ cells, indicating tissue-resident macrophage accumulation. D, Representative images 
are stained for Mac2 (green), α-SMA (red), and DAPI (blue). E, Assessment of macrophage proliferation by colocalization of KI67 within 
macrophages (Mac2). Representative images are stained for KI67 (red), Mac2 (green), and DAPI (blue). White arrows indicate proliferating 
macrophages (Mac2+/Ki67+ cells) F, Assessment of presence of M-CSF (macrophage colony-stimulating factor; %) in the neointima area. 
Scale bars represent 100 or 25 μm (right, panel D zoom). All data are presented as mean±SEM. Data were analyzed by unpaired t test. 
n=9 to 10. P values <0.05 were considered significant.
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in AnxA1-deficient mice may contribute to the phenotype 
observed in the present study. Moreover, macrophage pro-
liferation instigated by modified lipids and proinflammatory 
meditators in atherosclerotic lesions is a denominator of arterial 
macrophage accumulation.12 Herein, we found an increase in 
the number of proliferating macrophages in AnxA1-null mice, 
suggesting that AnxA1 acts as negative regulator of macrophage 
proliferation. In line with those findings, an elevated M-CSF 
staining in the neointima of AnxA1-deficient mice was found, 
as well as an inhibitory effect of recombinant AnxA1 on the 
expression and release of M-CSF by macrophages in vitro. By 
which mechanism AnxA1 controls M-CSF production in mac-
rophages and if this is of relevance also during advanced stages 
of atherosclerosis remain to be defined. Taken together, the phe-
notype observed in our model likely originates from a combi-
nation of augmented monocyte recruitment and the increased 
ability of arterial macrophages to proliferate in the absence of 
AnxA1 (Graphic Abstract in the online-only Data Supplement).
Therapeutic intervention with AnxA1 or its bioactive pep-
tide Ac2-26 have proven to be beneficial in mouse models of 
arterial vascular disease.5,13 Of note, it has been demonstrated 
that arterial-specific nanodelivery of Ac2-26 could be a prom-
ising tool to prevent atheroprogression, a strategy that may also 
be applicable to treatment of angioplasty-related side effects.14 
In line with previously successfully used FPR2 ligands,3 stents 
coated with AnxA1 protein could potentially be suitable to 
prevent lumen loss and inflammation after arterial injury.
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Highlights
• Annexin A1 is expressed by endothelial cells and macrophages in large arteries.
• Local and systemic annexin A1 levels negatively correlate with neoimtima sizes.
• Lack of annexin A1 exacerbates neointima formation by enhanced macrophage accumulation.
• Annexin A1 suppresses M-CSF (macrophage colony-stimulating factor) production and release.
